Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching

Coronary heart disease is a prevalent and fatal killer caused by vulnerable atherosclerotic plaques (VASPs). However, the precise detection and treatment of VASPs remains a difficult challenge. Here, we present the development of noninvasive human serum albumin (HSA)-based theranostic nanomedicines...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Sai, Motevalli, Seyed Mohammad, Chen, Jiangwei, Xu, Meng-Qi, Wang, Yabin, Feng, Jing, Qiu, Ya, Han, Dong, Fan, Miaomiao, Ding, Meiling, Fan, Li, Guo, Weisheng, Liang, Xing-Jie, Cao, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037040/
https://www.ncbi.nlm.nih.gov/pubmed/30026877
http://dx.doi.org/10.7150/thno.24364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037040/
https://www.ncbi.nlm.nih.gov/pubmed/30026877
http://dx.doi.org/10.7150/thno.24364

Ejemplares similares